Xoma Ltd.

2910 Seventh Street
Berkeley, CA 94710

USA

Phone: (510) 204-7200
Fax: (510) 644-0539
Email: investorrelations@xoma.com
Web Site: http://www.xoma.com/

A. Company Profile

Xoma (NASDAQ:XOMA) is a leader in discovery, development, and manufacture of therapeutic antibodies for multiple therapeutic targets, including cancer.

B. Products

Product Pipelines

1.      HCD122 Mab

HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.